Arvinas' Data From Phase 1 Trial Of Arv-102, Demonstra...

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy.ARV-102 was well tolerated across all dose levels following 28 days of once-daily

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy.
ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing.
Data support further development of ARV-102 in additional neurodegenerative diseases characterized by lysosomal dysfunction, including progressive supranuclear palsy, a rapidly progressing and devastating tauopathy

Arvinas&#39; Data From Phase 1 Trial Of Arv-102, Demonstrates Approximately 50% Or Greater Reduction Of LRRK2 In Cerebrospinal Fluid At All Doses By Day 14 And Maintaining The Reduction Through Day 28 In Parkinson&#39;s Disease Patients

Arvinas' Data From Phase 1 Trial Of Arv-102, Demonstrates Approximately 50% Or Greater Reduction Of LRRK2 In Cerebrospinal Fluid At All Doses By Day 14 And Maintaining The Reduction Through Day 28 In Parkinson's Disease Patients